Rekombinanter PD-1 Antikörper
Kurzübersicht für Rekombinanter PD-1 Antikörper (ABIN6940272)
Target
Alle PD-1 (PDCD1) Antikörper anzeigenAntikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Aufreinigung
- Purified by Protein A/G
-
Immunogen
- Recombinant human full-length PDCD1 protein
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
Positive Control: TY cells. Tonsil.
Known Application: Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT)(Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM Tris with 1 mM EDTA, pH 9.0, for 10-20 min followed by cooling at RT for 20 minutes)Optimal dilution for a specific application should be determined.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 200 μg/mL
-
Buffer
- 10 mM PBS with 0.05 % BSA & 0.05 % azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-80 °C
-
Informationen zur Lagerung
- Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.
-
Haltbarkeit
- 24 months
-
-
- PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))
-
Andere Bezeichnung
- PDCD1
-
Hintergrund
- PDCD-1 (programmed cell death-1 protein), also designated CD279, is a type I transmembrane receptor and a member of the immunoglobin gene superfamily. It is expressed on activated T-cells, B-cells, and myeloid cells. Anti-PDCD-1 is a marker of angioimmunoblastic lymphoma and suggests a unique cell of origin for this neoplasm. Unlike CD10 and BCL6, PDCD-1 is expressed by few B-cells, so anti-PDCD-1 may be a more specific and useful diagnostic marker in angioimmunoblastic lymphoma. In addition, PDCD-1 expression provides evidence that angioimmunoblastic lymphoma is a neoplasm derived from germinal center-associated T-cells.
-
Molekulargewicht
- 55kDa
-
Gen-ID
- 5133
-
UniProt
- Q15116
-
Pathways
- Cancer Immune Checkpoints
Target
-